Detalhe da pesquisa
1.
Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.
Respirology
; 28(5): 465-474, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36642509
2.
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
N Engl J Med
; 381(18): 1718-1727, 2019 10 31.
Artigo
Inglês
| MEDLINE | ID: mdl-31566307
3.
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
Respir Res
; 23(1): 85, 2022 Apr 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35392908
4.
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
Respir Res
; 22(1): 84, 2021 Mar 16.
Artigo
Inglês
| MEDLINE | ID: mdl-33726766
5.
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
Clin Exp Rheumatol
; 35 Suppl 106(4): 75-81, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28664834
6.
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
Respir Res
; 16: 116, 2015 Sep 24.
Artigo
Inglês
| MEDLINE | ID: mdl-26400368
7.
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD).
BMJ Open Respir Res
; 10(1)2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37709661
8.
A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting ß2-agonist, in patients with chronic obstructive pulmonary disease.
Respir Med
; 109(5): 606-15, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25776199